#196
|
||||
|
||||
Iatrogenic Adverse Events in the Coronary Care Unit
Iatrogenic Adverse Events in the Coronary Care Unit
Circ Cardiovasc Qual Outcomes Sherali A. Rahim, Anita Mody, Jennifer Pickering, P.J. Devereaux and Salim Yusuf [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#197
|
|||
|
|||
ìåíÿåì ñïåêòð èíñòðóìåíòà â êàòëàáå ñ ôåìîðàëüíîãî íà ðàäèàëüíûé
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#199
|
|||
|
|||
Äîëãî äóìàëà êóäà ïîìåñòèòü: ñþäà èëè â òåìó ïî ãåìîòðàíñôóçèè â òåðàïèè, ðåøèëà ñþäà, òàê êàê, ïðîñòî, ïîêàçàëîñü ëþáîïûòíûì
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
__________________
Ñ óâàæåíèåì |
#200
|
|||
|
|||
"Ñòâîëîâîé" ðåãèñòð (LE MANS registry)
Ïîõîæå, ÷òî ðåçóëüòàòû ðåãèñòðîâ ïî ñòåíòèðîâàíèþ LMCA äåëàþò ýòè÷íûì RCT ïî ñðàâíåíèþ ÒÁÊÀ vs ÀÊØ ó ýòîé êàòåãîðèè ïàöèåíòîâ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#201
|
|||
|
|||
|
#202
|
|||
|
|||
Óðîâåíü ïîâòîðíûõ ãîñïèòàëèçàöèé ïîñëå ÒÁÊÀ
Óðîâåíü ïîâòîðíûõ ãîñïèòàëèçàöèé ó ïàöèåíòîâ ïîñëå ÒÁÊÀ â òå÷åíèå 30 äíåé ïîñëå âûïèñêè èç ñòàöèîíàðà (ðåòðîñïåêòèâíûé àíàëèç; 315241 ïàöèåíò, 1108 êëèíèê) îêàçàëñÿ íåîæèäàííî âûñîêèì - 14.6%
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ñðåäè ïîâòîðíî ãîñïèòàëèçèðîâàííûõ ïîâòîðíàÿ ÒÁÊÀ âûïîëíåíà ó 25.8%, ÀÊØ - ó 1.7. Àâòîðû äåëàþò âûâîä î íåîáõîäèìîñòè èçó÷åíèÿ ýòîãî ôàêòà è ðàçðàáîòêè ìåð ïî ïðåäîòâðàùåíèþ îíîãî. |
#203
|
||||
|
||||
Advancing Anticoagulation in Cardiovascular Medicine: Perspectives on Future Oral Therapies
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#204
|
||||
|
||||
1.Guidelines on the prevention, diagnosis, and treatment of infective endocarditis
(new version 2009) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 2.Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 3.Guidelines for the diagnosis and treatment of pulmonary hypertension [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 4. Guidelines for the diagnosis and management of syncope (version 2009) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ôàéëû ïî÷åìó-òî íå çàêðûòû, ñêà÷èâàéòå ïîñêîðåå. |
#205
|
||||
|
||||
ESC Congress 2009 (ìîæåò áûòü íóæíà ðåãèñòðàöèÿ)
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] CURRENT OASIS 7: No overall benefit for higher doses of aspirin or clopidogrel, except in PCI subgroup [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] PLATO: Benefit of ticagrelor over clopidogrel in ACS [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] RE–LY: Dabigatran is superior with better safety than warfarin for AF prophylaxis [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] SEPIA-ACS 1 TIMI 42: Promising data on a new IV direct Factor Xa inhibitor [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] GISSI-HF: A reduction in AF with statins? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#206
|
||||
|
||||
NORDISTEMI: Benefit of invasive strategy following fibrinolysis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] TRIANA: Benefit of primary PCI in the elderly [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ISAR-TEST-4: Biodegradable DES hold up against permanent polymer-based DES [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] TRITON-TIMI 38: No increase in CV events with PPI and clopidogrel [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] PRAGUE-7: No benefit of pre-PCI abciximab in cardiogenic shock [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] AAA: No benefit of aspirin for primary prevention in PAD [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#207
|
||||
|
||||
"À ïî÷åìó îíè äîëæíû áûòü çàêðûòû? Èõ íà ñàéòå ESC íå çàêðûâàþò"
Çàêðûòû - ýòî çíà÷èò "çàìî÷åê" ñáîêó, òî åñòü èç ôàéëà íåëüçÿ êîïèðîâàòü è ïåðåâîäèòü ïåðåâîä÷èêîì. Äëÿ ìåíÿ ýòî èìååò çíà÷åíèå. Êàê ðàç ãàéäû ESC ïî÷òè âñåãäà çàêðûâàëèñü òàêèì îáðàçîì â îòëè÷èè îò ÀÑÑ/ÀÍÀ. |
#208
|
||||
|
||||
Ïðîäîëæàåì íîâîñòè ñ êîíãðåññà ESC 2009
KYOTO Heart Study: Benefits of add-on valsartan in hypertensive Japanese patients [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] PROTECT-Study: No benefit of rolofylline in acute HF [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ACTIVE-I: Irbesartan in AF – no overall benefit, but lower HF rehospitalization [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] MADIT-CRT: Reduction in HF admissions in asymptomatic LV dysfunction [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Âåñü êîíãðåññ: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#209
|
|||
|
|||
|
#210
|
||||
|
||||
|